1Two documents at two stages.
A Form 483 and a warning letter come from different people at different points. The investigator writes the 483 during the inspection and hands it over at the end. If FDA issues a warning letter, the decision is made by senior officials within FDA, often including the product centre, after “a thorough review of all of the relevant facts”.¹
| Form 483 | Warning letter | |
|---|---|---|
| What it is | Inspectional observations that, in the investigator’s judgement, may be violations of the FD&C Act | FDA’s notice of violations it considers of regulatory significance |
| Who issues it | The investigator, at the close of the inspection | A program office director, division director or higher FDA official, often with centre concurrence |
| Final? | Not “a final agency determination regarding your compliance” | “Informal and advisory”, and not final agency action |
| Response | Voluntary; FDA recommends one within 15 business days | Requested within a set period, usually 15 working days |
| Public? | Redacted copies can be released under FOIA | Posted on FDA’s warning letters page |
| Inspection classification | VAI or OAI | OAI whenever a warning letter is issued |
The table draws on FDA’s Form 483 FAQ, its 2009 notice on post-inspection responses, its March 2026 draft guidance on 483 responses, its Regulatory Procedures Manual, its warning letters page and a 2023 FDA webinar on drug inspections.²¹³⁴⁵⁶
2What a Form 483 records.
A 483 is issued to management at the end of an inspection when the investigator has observed conditions “that in their judgment may constitute violations” of the FD&C Act and related Acts. It is not a complete list of every problem, and it “does not constitute a final Agency determination”. FDA considers it together with the Establishment Inspection Report, the evidence collected and any response before deciding what to do.² The page on the Form 483 explains it in full.
3What a warning letter is.
FDA’s Regulatory Procedures Manual says warning letters “are issued only for violations of regulatory significance”, meaning violations “that may lead to enforcement action if not promptly and adequately corrected”. A warning letter is FDA’s “principal means of achieving prompt voluntary compliance” and also establishes prior notice. It is “informal and advisory”: it communicates FDA’s position but does not commit FDA to enforcement.⁴
The manual lists what warning letters have in common, including:⁴
- the title “WARNING LETTER”, addressed to the highest known official of the company;
- the dates of the inspection and the violations, citing the section of the Act and the regulation, such as section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B);
- a reply on the apparent adequacy of corrections promised during the inspection, annotated on the 483 or given in a written response;
- a request for correction and a written response, usually within 15 working days;
- a warning that failure to address the issues may result in regulatory or legal action;
- for drug letters citing CGMP, a statement that FDA may withhold export certificates and, where appropriate, approval of new applications that list the company as a manufacturer.
Warning letters are not only about manufacturing. FDA lists concerns such as poor manufacturing practices, problems with claims for what a product can do and incorrect directions for use,⁷ and a letter can come from work done at FDA headquarters or a centre rather than from an inspection.⁴
4How a 483 becomes a warning letter.
The manual’s general time frames give the program office 15 working days after the inspection to submit a warning letter recommendation, and the reviewing centre 15 working days to decide; for human drug inspections, a separate concept of operations sets them. CDER’s concurrence is required for CGMP charges on drug dosage forms and active ingredients.⁴ In deciding whether to issue one, FDA considers whether the evidence shows a violation, whether it is of regulatory significance and whether the company can be expected to correct it promptly.⁴
The company’s response matters, within limits. Ongoing or promised corrective actions “generally do not preclude the issuance of a Warning Letter”. As a general rule, a warning letter should not be issued if FDA concludes that the corrections are adequate and the violations corrected. FDA weighs the compliance history, the nature of the violation, the risk of the product, whether the corrective action reaches related products and facilities, whether it is documented and whether it will last.⁴ A response received within 15 business days of the 483 gets a detailed review before FDA decides, and FDA will not ordinarily delay a warning letter to review a later one.¹
Below the threshold for a warning letter sits the untitled letter. It cites violations that are not significant enough for a warning letter, carries no warning that enforcement may follow, and requests rather than requires a written response.⁴
5A warning letter is not a required step.
FDA is under no legal obligation to warn a company before taking enforcement action, except in a few defined areas. It may act without a warning letter when violations are repeated, intentional or flagrant, or present a reasonable possibility of injury or death.⁴ A 483 can therefore lead straight to other action, and a warning letter can be issued without any inspection.
6What happens after a warning letter.
The issuing office evaluates the response, and if the response is inadequate or missing, it follows up to achieve correction. The usual way to verify corrections is a follow-up inspection.⁴ FDA may then issue a close-out letter for warning letters issued on or after 1 September 2009, but only once the corrective actions have actually been made and verified by FDA, never on representations that they will be. No close-out letter is issued if the violations cannot by their nature be corrected.⁷
If the violations continue, FDA’s options include recall, seizure, injunction, administrative detention, civil money penalties and prosecution.⁴ An OAI classification can also mean that pending applications are not approved.⁶
7How it runs in Seal.
The inspection readiness blueprint logs each observation, from a Form 483 item to an audit finding, with the cited requirement and your response commitments. Follow-up actions link to CAPA and verification evidence links back to the observation, so an action is not treated as closed because a response letter was sent.
In the CAPA blueprint, the source deviation, investigation, actions, controlled change and follow-up evidence share one record. Closure can be configured to require the approved effectiveness review, and a failed or inconclusive check follows a reassessment path that keeps the earlier decision.
References
- 1Review of Post-Inspection Responses, notice, FDA, 74 FR 40211, 11 August 2009. https:/
/ www. federalregister. gov/ documents/ 2009/ 08/ 11/ E9- 19107/ review- of- post- inspection- responses (read 6 November 2026) - 2FDA Form 483 Frequently Asked Questions, FDA. https:/
/ www. fda. gov/ inspections- compliance- enforcement- and- criminal- investigations/ inspection- references/ fda- form- 483- frequently- asked- questions (read 6 November 2026) - 3Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection, draft guidance for industry, FDA, March 2026, section III.D. https:/
/ www. fda. gov/ regulatory- information/ search- fda- guidance- documents/ responding- fda- form- 483- observations- conclusion- drug- cgmp- inspection (read 6 November 2026) - 4Regulatory Procedures Manual, Chapter 4, Advisory Actions, sections 4-1-1, 4-1-3, 4-1-4, 4-1-7, 4-1-8, 4-1-10 and 4-2-1, FDA, July 2024. https:/
/ www. fda. gov/ media/ 71878/ download (read 6 November 2026) - 5Warning Letters, FDA. https:/
/ www. fda. gov/ inspections- compliance- enforcement- and- criminal- investigations/ compliance- actions- and- activities/ warning- letters (read 6 November 2026) - 6Overview of Drug Manufacturing Inspections, Understanding FDA Inspections and Data Webinar, FDA, 6 September 2023. https:/
/ www. fda. gov/ media/ 172786/ download (read 6 November 2026) - 7About Warning and Close-Out Letters, FDA, content current as of 20 March 2024. https:/
/ www. fda. gov/ inspections- compliance- enforcement- and- criminal- investigations/ warning- letters/ about- warning- and- close- out- letters (read 6 November 2026)
AQuestions and answers
Is a warning letter more serious than a 483?
Yes. A 483 records an investigator’s observations before FDA has reached a view. A warning letter means FDA has reviewed the case and considers the violations significant enough to lead to enforcement if they are not corrected, and the letter is made public.
Does every 483 lead to a warning letter?
No. FDA reviews the 483 with the inspection report, the evidence and the company’s response. An inspection with a 483 can end as Voluntary Action Indicated, which FDA treats as an acceptable state of compliance, and a warning letter should not generally be issued if FDA finds the violations already corrected.
How long do you have to respond to a warning letter?
The letter sets the period, usually 15 working days from receipt. The response should cover each step taken or planned to correct the violations and prevent them recurring, when each will be complete, why any action is not finished and the documents that show correction.
Can FDA issue a warning letter without an inspection?
Yes. Warning letters can come from work at FDA headquarters or a centre, and FDA uses them for problems with what a product claims to do or with its directions for use, as well as for manufacturing failures.
What is a close-out letter?
A close-out letter tells a company that FDA has evaluated its corrective actions and is satisfied that the violations in a warning letter have been addressed. FDA issues one only after the corrections have been made and verified, usually by a follow-up inspection, and never on promises alone.
What is an untitled letter?
An untitled letter cites violations that do not reach the level of significance for a warning letter. It has no title, includes no warning that enforcement may follow and asks for, rather than requires, a written response.